International consensus on the use of tau PET imaging agent 18F-flortaucipir in Alzheimer’s disease

Abstract Purpose Positron emission tomography (PET) with the first and only tau targeting radiotracer of 18F-flortaucipir approved by FDA has been increasingly used in depicting tau pathology deposition and distribution in patients with cognitive impairment. The goal of this international consensus is to help nuclear medicine practitioners procedurally perform 18F-flortaucipir PET imaging. Method A multidisciplinary task group formed by experts from various countries discussed and approved the consensus for 18F-flortaucipir PET imaging in Alzheimer’s disease (AD), focusing on clinical scenarios, patient preparation, and administered activities, as well as image acquisition, processing, interpretation, and reporting. Conclusion This international consensus and practice guideline will help to promote the standardized use of 18F-flortaucipir PET in patients with AD. It will become an international standard for this purpose in clinical practice.

Download Full-text

Significant effects of cholinesterase inhibitors on tau pathology in the Alzheimer's disease continuum: An in vivo positron emission tomography study

International Journal of Geriatric Psychiatry ◽

10.1002/gps.5522 ◽

2021 ◽

Author(s):

Fumihiko Yasuno ◽

Hiroyuki Minami

Keyword(s):

Alzheimer’S Disease ◽

Alzheimer's Disease ◽

Positron Emission Tomography ◽

Cholinesterase Inhibitors ◽

Emission Tomography ◽

Positron Emission Tomography Study ◽

Tau Pathology ◽

Positron Emission

Download Full-text

Improving PET Imaging Acquisition and Analysis With Machine Learning: A Narrative Review With Focus on Alzheimer's Disease and Oncology

Molecular Imaging ◽

10.1177/1536012119869070 ◽

2019 ◽

Vol 18 ◽

pp. 153601211986907 ◽

Cited By ~ 3

Author(s):

Ian R. Duffy ◽

Amanda J. Boyle ◽

Neil Vasdev

Keyword(s):

Artificial Intelligence ◽

Machine Learning ◽

Alzheimer’S Disease ◽

Alzheimer's Disease ◽

Pet Imaging ◽

Accurate Diagnosis ◽

Emission Tomography ◽

Treatment Regimens ◽

Positron Emission ◽

Digital Biomarkers

Machine learning (ML) algorithms have found increasing utility in the medical imaging field and numerous applications in the analysis of digital biomarkers within positron emission tomography (PET) imaging have emerged. Interest in the use of artificial intelligence in PET imaging for the study of neurodegenerative diseases and oncology stems from the potential for such techniques to streamline decision support for physicians providing early and accurate diagnosis and allowing personalized treatment regimens. In this review, the use of ML to improve PET image acquisition and reconstruction is presented, along with an overview of its applications in the analysis of PET images for the study of Alzheimer's disease and oncology.

Download Full-text

Tauvid™: The First FDA-Approved PET Tracer for Imaging Tau Pathology in Alzheimer’s Disease

Pharmaceuticals ◽

10.3390/ph14020110 ◽

2021 ◽

Vol 14 (2) ◽

pp. 110

Author(s):

Caitlin Jie ◽

Valerie Treyer ◽

Roger Schibli ◽

Linjing Mu

Keyword(s):

Alzheimer’S Disease ◽

Alzheimer's Disease ◽

Pet Imaging ◽

Second Generation ◽

Tau Proteins ◽

Tau Pathology ◽

Pet Tracer ◽

Positron Emission ◽

Tau Pet ◽

Target Binding

Tauvid has been approved by the U.S. Food and Drug Administration (FDA) in 2020 for positron emission tomography (PET) imaging of adult patients with cognitive impairments undergoing evaluation for Alzheimer’s disease (AD) based on tau pathology. Abnormal aggregation of tau proteins is one of the main pathologies present in AD and is receiving increasing attention as a diagnostic and therapeutic target. In this review, we summarised the production and quality control of Tauvid, its clinical application, pharmacology and pharmacokinetics, as well as its limitation due to off-target binding. Moreover, a brief overview on the second-generation of Tau PET tracers is provided. The approval of Tauvid marks a step forward in the field of AD research and opens up opportunities for second-generation tau tracers to advance tau PET imaging in the clinic.

Download Full-text

Biomarkers for Alzheimer’s disease

Oxford Textbook of Old Age Psychiatry ◽

10.1093/med/9780198807292.003.0006 ◽

2020 ◽

pp. 99-116

Author(s):

Andrea Vergallo ◽

Harald Hampel ◽

René S. Bun ◽

Simone Lista

Keyword(s):

Alzheimer’S Disease ◽

Alzheimer's Disease ◽

Pet Imaging ◽

Dynamic Range ◽

Emission Tomography ◽

Csf Biomarkers ◽

Serum Proteomics ◽

Positron Emission ◽

T Tau ◽

Technological Platforms

Reflecting the neuropathological hallmarks of Alzheimer’s disease (AD), cerebrospinal fluid (CSF) concentrations of Aβ‎1-42, t-tau, and p-tau and positive amyloid positron emission tomography (PET) imaging are considered core biomarkers for AD. Unfortunately, their use for screening is limited by their invasive nature (CSF biomarkers) or high cost (PET imaging). Among the biologic specimens that may be scrutinized for identifying novel AD biomarkers, circulating blood is a convenient source for sampling. The dynamic range of high-throughput technological platforms, coupled with advances in bioinformatics, holds the promise that proteomics will be a significant contributor to the field of blood-based AD biomarkers. Here, the chapter summarizes the blood-based biomarker platforms applied to the investigation of AD and reviews recent achievements in plasma/serum proteomics related to AD. These findings set the stage for the implementation of systems biology in the context of the evolving precision medicine paradigm for AD.

Download Full-text